CA2078759C — Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
Assigned to Aventis Pharmaceuticals Inc · Expires 2003-09-16 · 23y expired
What this patent protects
The present invention relates to compounds of the formula (see Formula I) wherein B1 and B2 are each independently hydrogen; hydroxy; -OR2 wherein R2 is a C1-C4 alkyl or an Ar-Y group wherein Ar is aryl and Y is a hydrogen or C1-C4 alkyl; or, where B1 and B2 are attached to adjac…
USPTO Abstract
The present invention relates to compounds of the formula (see Formula I) wherein B1 and B2 are each independently hydrogen; hydroxy; -OR2 wherein R2 is a C1-C4 alkyl or an Ar-Y group wherein Ar is aryl and Y is a hydrogen or C1-C4 alkyl; or, where B1 and B2 are attached to adjacent carbon atoms, B1 and B2 can be taken together with said adjacent carbons to form a benzene ring or methylenedioxy; A is a bond, methylene or oxygen, sulfur or NR4 or NCOR5 wherein R4 is hydrogen, a C1-C4 alkyl or an Ar-Y- group and R5 is -CF3, a C1-C10 alkyl or an Ar-Y- group; R3 is hydrogen or -CH2OC(O)C(CH3)3; R1 is hydrogen, C1-C4 alkyl or -CH2OC(O)-C(CH3)3; and n is an integer 1 to 3, which are useful as inhibitors of enkephalinase and ACE.
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.